Patent: 10,653,793
✉ Email this page to a colleague
Summary for Patent: 10,653,793
| Title: | Antibody-drug conjugates and uses thereof |
| Abstract: | The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan. |
| Inventor(s): | Goldenberg; David M. (Mendham, NJ), Govindan; Serengulam V. (Summit, NJ) |
| Assignee: | Immunomedics, Inc. (Morris Plains, NJ) |
| Application Number: | 16/143,680 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,653,793
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2032-12-13 |
| Bristol-myers Squibb Company | YERVOY | ipilimumab | Injection | 125377 | 03/25/2011 | ⤷ Try a Trial | 2032-12-13 |
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2032-12-13 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
